InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2024-04-19 00:00:00 ET · period of report 2024-04-17 · accession 0001415889-24-011252 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-04-19 2024-04-17 JBIO Dake Benjamin T SEE REMARKS S - Sale+OE $22.38 -6,853 1,359 -83% -$153.4K
D 2024-04-19 2024-04-17 JBIO Dake Benjamin T SEE REMARKS M - OptEx $2.14 +6,853 8,144 +531% +$14.7K
D 2024-04-19 2024-04-17 JBIO Dake Benjamin T SEE REMARKS M - OptEx $0.00 -6,853 95.9K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-04-17 S D 6,447 $22.32 1,697 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.812 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
2 Common Common Stock 2024-04-17 S D 68 $23.97 1,291 D — —
3 Common Common Stock 2024-04-17 S D 338 $23.17 1,359 D — — (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.825 to $23.65, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
4 Common Common Stock 2024-04-17 M A 6,853 $2.14 8,144 D — —
5 Derivative Stock Option (Right to Buy) 2024-04-17 M D 6,853 $0.00 95,936 D $2.14 · — to 2031-04-01 6,853 Common Stock (F4) A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.